CAR-T stands for Chimeric Antigen Receptor T-cell Therapy, an innovative form of immunotherapy that reprograms a patient’s own T cells to identify and destroy cancer cells. By utilizing the body’s immune system, CAR-T therapy provides a highly personalized treatment approach for selected cancers.

The treatment begins by collecting T cells from the patient’s blood. These cells are genetically engineered in our advanced laboratories to express Chimeric Antigen Receptors (CARs). Once expanded into millions of therapeutic cells, they are infused back into the patient where they recognize, attack, and destroy cancer cells.

CAR-T therapy has shown remarkable success in treating several blood cancers including:

• Acute Lymphoblastic Leukemia (ALL)
• Non-Hodgkin Lymphoma (NHL)
• Multiple Myeloma (MM)
• Chronic Lymphocytic Leukemia (CLL)

Essen BioTech continues to expand CAR-T applications through ongoing research and clinical development for additional cancer indications.

1. Collecting T Cells

Your treatment begins with a blood collection procedure where healthy T cells are safely collected.

2. Genetic Modification & Expansion

The collected cells are genetically engineered with CAR technology and multiplied in our GMP laboratories.

3. Infusion & Monitoring

The engineered CAR-T cells are infused back into your body where they actively target cancer cells while our clinical team closely monitors your recovery and treatment response.

• Compassionate, patient-centered care
• World-class oncologists and scientific experts
• Advanced GMP manufacturing facilities
• Strict international quality and safety standards
• Continuous support throughout every stage of treatment

CAR-T therapy represents more than an advanced medical treatment—it reflects our commitment to innovation, scientific excellence, and personalized patient care. At Essen BioTech, we walk beside every patient throughout their treatment journey, providing hope through next-generation cellular therapies.